ENDRA Life Sciences Inc. (NDRA) |
| 5.61 0.07 (1.26%) 07-15 16:00 |
| Open: | 5.32 |
| High: | 5.89 |
| Low: | 5.32 |
| Volume: | 17,990 |
| Market Cap: | 4(M) |
| PE Ratio: | -0.72 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 7.79 |
| Resistance 1: | 6.67 |
| Pivot price: | 5.19 |
| Support 1: | 4.77 |
| Support 2: | 3.60 |
| 52w High: | 9.85 |
| 52w Low: | 2.96 |
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
| EPS | -8.340 |
| Book Value | 1.440 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -122.3 |
| Return on Equity (ttm) | -412.6 |
Thu, 25 Jun 2026
ENDRA Life Sciences Inc. Actuals & Estimates (NASDAQ:NDRA) - TradingView
Thu, 25 Jun 2026
ASP Isotopes' Noble Africa unit to merge with ENDRA Life Sciences unit in $50M deal (ASPI:NASDAQ) - Seeking Alpha
Thu, 25 Jun 2026
ENDRA Life Sciences (NDRA) proposes merger of subsidiary with Noble Africa - Stock Titan
Thu, 25 Jun 2026
NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders - marketscreener.com
Thu, 25 Jun 2026
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing - Yahoo Finance
Thu, 18 Jun 2026
ENDRA Life Sciences Inc (NDRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |